RNA療法市場：技術、適応症、エンドユーザー別-2024-2030年の世界予測

RNA療法市場規模は2023年に21億8,000万米ドルと推計され、2024年には26億米ドルに達し、CAGR 22.38％で2030年には89億8,000万米ドルに達すると予測されています。

RNA療法には、特定の遺伝子配列や細胞メカニズムを標的とするリボ核酸（RNA）分子を利用した治療アプローチの開発と商業化が含まれます。これらの治療法は、RNA分子を標的とすることで、欠陥のある遺伝子を置き換えたり、有害な遺伝子発現を抑制したり、細胞機能を調節したりして、様々な疾患や状態を治療します。バイオテクノロジー新興企業への投資の増加、アカデミアと産業界のプレーヤー間の協力関係の拡大、アンメット・メディカル・ニーズに対する潜在的な治療標的のポートフォリオの拡大が、RNA療法の必要性を高めています。希少疾病用医薬品の指定や迅速な承認など、規制当局の好意的な政策により、いくつかのRNAベースの治療法の臨床開発が加速しています。生体内におけるRNA分子の不安定性と急速な分解に関連する送達課題が、市場成長の妨げとなっています。治療の選択肢が限られている希少疾患に対する新規RNA治療への最先端技術の活用を目指す製薬企業による継続的な進歩が、市場成長の機会を生み出すと期待されています。

技術：イネーブルド・テクノロジーに対する需要の高まりがRNA療法の進歩を促進します。

イネーブルド・テクノロジーは、RNA分子を正確に操作して標的細胞に送達するために必要なツールを提供するため、RNA療法の進歩を促進します。この技術は、低分子干渉RNA（siRNA）を細胞に導入することにより、特定の遺伝子をサイレンシングします。実現技術は、改良されたRNA分子の設計、合成、改変、送達方法を提供することにより、実現技術の開発と応用を促進します。RNA干渉（RNAi）、アンチセンス・オリゴヌクレオチド（ASO）、メッセンジャー・リボ核酸（mRNA）治療薬などのイネーブルド・テクノロジーは、標的とする疾患メカニズムに応じて遺伝子発現を調節するための異なるアプローチを提供します。

適応症RNA療法の遺伝性疾患やがん疾患への広範な応用。

RNA療法は、特定のがん遺伝子やがん抑制遺伝子を標的とするがん治療において極めて重要です。これらの治療法は、がん細胞でしばしば破壊される遺伝子発現を制御するのに役立ちます。がんにおけるRNA療法の必要性に基づく選好には、患者の遺伝子構成に合わせた個別化治療が含まれます。RNA療法は、疾患関連遺伝子の発現を調節することにより、心不全や高血圧などの心血管系疾患の治療に応用できる可能性があります。重度あるいは希少な心血管疾患の患者は、従来の治療法に比べて副作用が少なく、有効性が高いため、このような標的治療の恩恵を受ける可能性があります。RNA療法は、単一遺伝子の変異や欠損によって引き起こされる遺伝性疾患の治療に用いることができます。この必要性に基づいた優先順位は、治療選択肢が限られている、希少で生命を脅かす遺伝性疾患の患者に焦点を当てています。RNA療法は宿主の免疫反応を調節したり、病原体を直接標的にすることにより、COVID-19、B型肝炎、結核などのウイルスや細菌感染と闘うことができます。薬剤耐性感染症に罹患している患者や、感染症の流行時に迅速な対応が必要な患者を優先しています。RNA療法は、腎機能や線維化に関与する特定の遺伝子を標的とすることで、多発性嚢胞腎や糖尿病性腎症などの慢性腎疾患に新たな治療選択肢を提供します。RNA療法は、グルコースおよび脂質代謝に関与する主要遺伝子を制御することにより、肥満、非アルコール性脂肪性肝炎（NASH）、2型糖尿病などの代謝性疾患を治療する可能性があります。がんワクチンに加え、RNA療法は、患者特異的腫瘍抗原をコードすることにより、様々な腫瘍タイプに対する個別化免疫療法の開発に使用されます。この必要性に基づいた嗜好性は、標準的な治療法にあまり反応しない攻撃性のがんや転移性のがんの患者をターゲットとしています。RNA療法は、影響を受けた遺伝子の機能的コピーを網膜細胞に直接送達することにより、レーバー先天性黒内障や加齢黄斑変性症などの遺伝子変異によって引き起こされる網膜疾患の治療に役立ちます。

エンドユーザー：診断薬や医薬品開発を推進する新発見に焦点を当てた学術研究が重視されつつあります。

学術研究では、遺伝子の機能と制御を理解するために、主にRNA療法が利用されています。研究者は、低分子干渉RNA（siRNA）、アンチセンスオリゴヌクレオチド（ASO）、マイクロRNA（miRNA）、メッセンジャーRNA（mRNA）治療薬など、さまざまなRNA治療アプローチを採用しています。RNAベースの診断法は、標的配列決定や遺伝子発現プロファイリングによる疾患特異的バイオマーカーの検出に重点を置いています。これらの診断法は、従来のDNAベースの手法に比べて感度が向上しています。RNAを標的とした創薬と開発には、新規治療標的の同定、選択的RNA結合低分子またはオリゴヌクレオチドの設計、細胞障害を克服する革新的デリバリーシステムの開発が含まれます。

地域別インサイト

南北アメリカのRNA療法市場は、発達したヘルスケアセクターと政府の支援プログラムによって支えられており、米国とカナダでは最先端のRNA治療薬がかなり商業化され、南米諸国では製薬産業が発展しています。南北アメリカの政府は、より良いヘルスケアシステムを人々に提供し、全体的な経済成長と公共の福祉に貢献するため、技術の進歩と研究活動を奨励しています。日本、インド、中国、韓国などのアジア太平洋地域の新興経済諸国や先進経済諸国の政府は、RNA療法の研究開発を奨励しています。欧州では、医療従事者がRNA療法を使用できるように、新しい機器や技術が急速に商業化され、受け入れられているため、RNA療法が大幅に採用されています。一方、欧州では老年人口が急増しており、いくつかの感染症や慢性疾患の適応症が増加すると予想されています。人口問題研究所（PRB）によると、ロシア、ドイツ、イタリア、フランス、英国、スペイン、トルコ、ウクライナ、ポーランド、ナイジェリア、イランは、65歳以上の人口比率が高い国々です。欧州の高齢化社会と障害の兆候が高まっているため、効率的なRNA治療が必要とされています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスはRNA療法市場の評価において極めて重要です。事業戦略と製品満足度に関連する主要指標を調査し、ベンダーの包括的な評価を提供します。この綿密な分析により、ユーザーは各自の要件に沿った十分な情報に基づいた意思決定を行うことができます。評価に基づき、ベンダーは成功の度合いが異なる4つの象限に分類されます：フォアフロント（F）、パスファインダー（P）、ニッチ（N）、バイタル（V）です。

市場シェア分析

市場シェア分析は、RNA療法市場におけるベンダーの現状について、洞察に満ちた詳細な調査を提供する包括的なツールです。全体的な収益、顧客基盤、その他の主要指標についてベンダーの貢献度を綿密に比較・分析することで、企業の業績や市場シェア争いの際に直面する課題について理解を深めることができます。さらに、この分析により、調査対象基準年に観察された蓄積、断片化の優位性、合併の特徴などの要因を含む、この分野の競合特性に関する貴重な考察が得られます。このような詳細レベルの拡大により、ベンダーはより多くの情報に基づいた意思決定を行い、市場で競争優位に立つための効果的な戦略を考案することができます。

本レポートは、以下の側面に関する貴重な洞察を提供しています：

1.市場の浸透度：主要企業が提供する市場に関する包括的な情報を提示しています。

2.市場の開拓度：有利な新興市場を深く掘り下げ、成熟市場セグメントにおける浸透度を分析しています。

3.市場の多様化：新製品の発売、未開拓の地域、最近の開発、投資に関する詳細な情報を提供します。

4.競合の評価と情報：市場シェア、戦略、製品、認証、規制状況、特許状況、主要企業の製造能力などを網羅的に評価します。

5.製品開発およびイノベーション：将来の技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような主要な質問に対応しています：

1.RNA療法市場の市場規模および予測は？

2.RNA療法市場の予測期間中に投資を検討すべき製品、セグメント、用途、分野は何か？

3.RNA療法市場の技術動向と規制枠組みは？

4.RNA療法市場における主要ベンダーの市場シェアは？

5.RNA療法市場への参入に適した形態や戦略的手段は？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 疾患病理におけるRNAの役割についての理解が深まる
    • 個別化医療の需要の高まり
    • 製薬企業による戦略的提携による新規医薬品開発の促進
  • 抑制要因
    • RNA療法開発プロセスに関連する高コスト
  • 機会
    • 政府および民間組織による研究開発活動への投資の増加
    • RNAベースの治療薬の臨床試験のパイプライン
  • 課題
    • RNA分子の不安定性から生じる問題と厳格な規制ガイドライン
• 市場セグメンテーション分析
  • テクノロジー：RNA療法の進歩を促進する技術に対する需要が高まっています。
  • 適応症：遺伝性疾患およびがん疾患におけるRNA療法の広範な応用。
  • エンドユーザー：診断と医薬品開発を推進する新たな発見に焦点を当てた学術調査の重要性が高まっています。
• 市場動向分析
• 高インフレの累積的影響
• ポーターのファイブフォース分析
• バリューチェーンとクリティカルパス分析
• 規制枠組みの分析
• 顧客のカスタマイズ

第6章 RNA療法市場：技術別

• 実現可能なテクノロジー
• 実現技術

第7章 RNA療法市場適応症別

• がん
• 心臓血管
• 遺伝性疾患
• 感染症
• 腎臓疾患
• 代謝障害
• 腫瘍学
• 網膜疾患

第8章 RNA療法市場：エンドユーザー別

• 学術調査
• 診断
• 医薬品の発見と開発

第9章 南北アメリカのRNA療法市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域のRNA療法市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカのRNA療法市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス、2023
• 競合シナリオ分析
  • 次世代RNA治療薬のリーダーであるADARx Pharmaceuticalsが、応募超過となった2億米ドルのシリーズC資金調達を発表
  • ReNAgade Therapeuticsが3億米ドルでRNA療法アリーナに参入
  • エスペロバックスとギンゴ・バイオワークスが環状RNAベースの治療薬開発で提携を発表

第13章 競合ポートフォリオ

• 主要企業プロファイル
• 主要製品ポートフォリオ

LIST OF FIGURES

• FIGURE 1. RNA THERAPY MARKET RESEARCH PROCESS
• FIGURE 2. RNA THERAPY MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2030 (%)
• FIGURE 5. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. RNA THERAPY MARKET DYNAMICS
• FIGURE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
• FIGURE 8. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 9. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
• FIGURE 10. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 11. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2030 (%)
• FIGURE 12. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 13. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 14. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 15. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 16. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 17. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 18. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 20. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 21. RNA THERAPY MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 22. RNA THERAPY MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. RNA THERAPY MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL RNA THERAPY MARKET SIZE, 2018-2023 (USD MILLION)
• TABLE 4. GLOBAL RNA THERAPY MARKET SIZE, 2024-2030 (USD MILLION)
• TABLE 5. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
• TABLE 6. GLOBAL RNA THERAPY MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
• TABLE 7. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 8. GLOBAL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 9. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 10. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 11. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 12. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 13. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 14. GLOBAL RNA THERAPY MARKET SIZE, BY INHIBITION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 15. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2018-2023 (USD MILLION)
• TABLE 16. GLOBAL RNA THERAPY MARKET SIZE, BY LABELING, BY REGION, 2024-2030 (USD MILLION)
• TABLE 17. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 18. GLOBAL RNA THERAPY MARKET SIZE, BY LINEAR AMPLIFICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 19. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 20. GLOBAL RNA THERAPY MARKET SIZE, BY MICROARRAYS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 21. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2018-2023 (USD MILLION)
• TABLE 22. GLOBAL RNA THERAPY MARKET SIZE, BY PURIFICATION, BY REGION, 2024-2030 (USD MILLION)
• TABLE 23. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 24. GLOBAL RNA THERAPY MARKET SIZE, BY QRT-PCR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 25. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 26. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 27. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 28. GLOBAL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 29. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 30. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 31. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 32. GLOBAL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 33. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 34. GLOBAL RNA THERAPY MARKET SIZE, BY MICRORNA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 35. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2018-2023 (USD MILLION)
• TABLE 36. GLOBAL RNA THERAPY MARKET SIZE, BY SMALL INTERFERING RNA, BY REGION, 2024-2030 (USD MILLION)
• TABLE 37. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 38. GLOBAL RNA THERAPY MARKET SIZE, BY RNA INTERFERENCE TECHNOLOGIES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 39. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 40. GLOBAL RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 41. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2018-2023 (USD MILLION)
• TABLE 42. GLOBAL RNA THERAPY MARKET SIZE, BY CANCER, BY REGION, 2024-2030 (USD MILLION)
• TABLE 43. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2023 (USD MILLION)
• TABLE 44. GLOBAL RNA THERAPY MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2024-2030 (USD MILLION)
• TABLE 45. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 46. GLOBAL RNA THERAPY MARKET SIZE, BY GENETIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 47. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 48. GLOBAL RNA THERAPY MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 49. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 50. GLOBAL RNA THERAPY MARKET SIZE, BY KIDNEY DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 51. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 52. GLOBAL RNA THERAPY MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 53. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
• TABLE 54. GLOBAL RNA THERAPY MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
• TABLE 55. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2018-2023 (USD MILLION)
• TABLE 56. GLOBAL RNA THERAPY MARKET SIZE, BY RETINAL DISEASES, BY REGION, 2024-2030 (USD MILLION)
• TABLE 57. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 58. GLOBAL RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 59. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2018-2023 (USD MILLION)
• TABLE 60. GLOBAL RNA THERAPY MARKET SIZE, BY ACADEMIC RESEARCH, BY REGION, 2024-2030 (USD MILLION)
• TABLE 61. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2023 (USD MILLION)
• TABLE 62. GLOBAL RNA THERAPY MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2024-2030 (USD MILLION)
• TABLE 63. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2018-2023 (USD MILLION)
• TABLE 64. GLOBAL RNA THERAPY MARKET SIZE, BY DRUG DISCOVERY & DEVELOPMENT, BY REGION, 2024-2030 (USD MILLION)
• TABLE 65. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 66. AMERICAS RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 67. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 68. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 69. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 70. AMERICAS RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 71. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 72. AMERICAS RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 73. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 74. AMERICAS RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 75. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 76. AMERICAS RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 77. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 78. AMERICAS RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 79. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 80. ARGENTINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 81. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 82. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 83. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 84. ARGENTINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 85. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 86. ARGENTINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 87. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 88. ARGENTINA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 89. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 90. ARGENTINA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 91. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 92. BRAZIL RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 93. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 94. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 95. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 96. BRAZIL RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 97. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 98. BRAZIL RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 99. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 100. BRAZIL RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 101. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 102. BRAZIL RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 103. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 104. CANADA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 105. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 106. CANADA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 107. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 108. CANADA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 109. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 110. CANADA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 111. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 112. CANADA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 113. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 114. CANADA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 115. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 116. MEXICO RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 117. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 118. MEXICO RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 119. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 120. MEXICO RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 121. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 122. MEXICO RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 123. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 124. MEXICO RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 125. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 126. MEXICO RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 127. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 128. UNITED STATES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 129. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 130. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 131. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 132. UNITED STATES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 133. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 134. UNITED STATES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 135. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 136. UNITED STATES RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 137. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 138. UNITED STATES RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 139. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
• TABLE 140. UNITED STATES RNA THERAPY MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
• TABLE 141. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 142. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 143. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 144. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 145. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 146. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 147. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 148. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 149. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 150. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 151. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 152. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 153. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 154. ASIA-PACIFIC RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 155. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 156. AUSTRALIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 157. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 158. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 159. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 160. AUSTRALIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 161. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 162. AUSTRALIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 163. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 164. AUSTRALIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 165. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 166. AUSTRALIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 167. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 168. CHINA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 169. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 170. CHINA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 171. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 172. CHINA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 173. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 174. CHINA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 175. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 176. CHINA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 177. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 178. CHINA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 179. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 180. INDIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 181. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 182. INDIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 183. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 184. INDIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 185. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 186. INDIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 187. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 188. INDIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 189. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 190. INDIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 191. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 192. INDONESIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 193. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 194. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 195. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 196. INDONESIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 197. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 198. INDONESIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 199. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 200. INDONESIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 201. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 202. INDONESIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 203. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 204. JAPAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 205. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 206. JAPAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 207. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 208. JAPAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 209. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 210. JAPAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 211. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 212. JAPAN RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 213. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 214. JAPAN RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 215. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 216. MALAYSIA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 217. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 218. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 219. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 220. MALAYSIA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 221. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 222. MALAYSIA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 223. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 224. MALAYSIA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 225. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 226. MALAYSIA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 227. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 228. PHILIPPINES RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 229. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 230. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 231. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 232. PHILIPPINES RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 233. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 234. PHILIPPINES RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 235. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 236. PHILIPPINES RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 237. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 238. PHILIPPINES RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 239. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 240. SINGAPORE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 241. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 242. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 243. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 244. SINGAPORE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 245. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 246. SINGAPORE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 247. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 248. SINGAPORE RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 249. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 250. SINGAPORE RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 251. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 252. SOUTH KOREA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 253. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 254. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 255. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 256. SOUTH KOREA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 257. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 258. SOUTH KOREA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 259. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 260. SOUTH KOREA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 261. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 262. SOUTH KOREA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 263. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 264. TAIWAN RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 265. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 266. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 267. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 268. TAIWAN RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 269. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 270. TAIWAN RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 271. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 272. TAIWAN RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 273. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 274. TAIWAN RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 275. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 276. THAILAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 277. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 278. THAILAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 279. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 280. THAILAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 281. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 282. THAILAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 283. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 284. THAILAND RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 285. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 286. THAILAND RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 287. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 288. VIETNAM RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 289. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 290. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 291. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 292. VIETNAM RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 293. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 294. VIETNAM RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 295. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 296. VIETNAM RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 297. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 298. VIETNAM RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 299. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 300. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 301. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 302. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 303. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 304. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 305. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 306. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 307. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 308. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 309. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 310. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 311. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
• TABLE 312. EUROPE, MIDDLE EAST & AFRICA RNA THERAPY MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
• TABLE 313. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 314. DENMARK RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 315. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 316. DENMARK RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 317. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 318. DENMARK RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 319. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 320. DENMARK RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 321. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 322. DENMARK RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 323. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 324. DENMARK RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 325. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 326. EGYPT RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 327. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 328. EGYPT RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 329. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 330. EGYPT RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 331. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 332. EGYPT RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 333. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 334. EGYPT RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 335. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 336. EGYPT RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 337. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 338. FINLAND RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 339. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 340. FINLAND RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 341. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 342. FINLAND RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 343. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 344. FINLAND RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 345. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 346. FINLAND RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 347. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 348. FINLAND RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 349. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 350. FRANCE RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2024-2030 (USD MILLION)
• TABLE 351. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 352. FRANCE RNA THERAPY MARKET SIZE, BY ENABLED TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 353. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 354. FRANCE RNA THERAPY MARKET SIZE, BY ENABLING TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 355. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2018-2023 (USD MILLION)
• TABLE 356. FRANCE RNA THERAPY MARKET SIZE, BY RNA ANTISENSE TECHNOLOGIES, 2024-2030 (USD MILLION)
• TABLE 357. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
• TABLE 358. FRANCE RNA THERAPY MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
• TABLE 359. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2018-2023 (USD MILLION)
• TABLE 360. FRANCE RNA THERAPY MARKET SIZE, BY END USER, 2024-2030 (USD MILLION)
• TABLE 361. GERMANY RNA THERAPY MARKET SIZE, BY TECHNOLOGY, 2018-2023 (USD MILLION)
• TABLE 362. GERMANY RNA THERAPY MARKET SIZE, BY TE

[187 Pages Report] The RNA Therapy Market size was estimated at USD 2.18 billion in 2023 and expected to reach USD 2.60 billion in 2024, at a CAGR 22.38% to reach USD 8.98 billion by 2030.

RNA therapy includes developing and commercializing therapeutic approaches that utilize ribonucleic acid (RNA) molecules to target specific genetic sequences and cellular mechanisms. These therapies treat various diseases and conditions by replacing faulty genes, silencing harmful gene expressions, or modulating cellular functions by targeting RNA molecules. Increasing investments in biotechnology startups, growing collaborations between academia and industry players, and an expanding portfolio of potential therapeutic targets for unmet medical needs drive the need for RNA therapies. Favorable regulatory policies for orphan drug designation and fast-track approvals have accelerated the clinical development of several RNA-based therapies. Delivery challenges associated with instability and rapid degradation of RNA molecules in vivo hampers market growth. Ongoing advancements by pharmaceutical companies to leverage cutting-edge technologies into novel RNA treatments for rare diseases with limited treatment options are expected to create opportunities for market growth.

Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.

Enabled technology drives the advancement in RNA therapy as it provides the tools necessary for precisely manipulating and delivering RNA molecules to target cells. This technology silences specific genes by introducing small interfering RNAs (siRNAs) into cells. Enabling technologies facilitate the development and application of enabled technologies by providing improved RNA molecule design, synthesis, modification, and delivery methods. Enabled technologies such as RNA interference (RNAi), Antisense Oligonucleotides (ASOs), and messenger Ribonucleic Acid (mRNA) therapeutics offer different approaches to modulating gene expression depending on the targeted disease mechanism.

Indication: Widespread applications of RNA therapy in genetic and cancer diseases.

RNA therapy is crucial in cancer treatment by targeting specific oncogenes or tumor suppressor genes. These therapies help to regulate gene expression, which is often disrupted in cancerous cells. Need-based preference for RNA therapy in cancer includes personalized treatments tailored to the patient's genetic makeup. RNA therapy has potential applications for treating cardiovascular diseases such as heart failure and hypertension by modulating the expression of disease-related genes. Patients with severe or rare cardiovascular conditions may benefit from these targeted therapies as they offer fewer side effects and better efficacy compared to conventional treatments. RNA therapy can be used to treat genetic disorders caused by mutations or deficiencies in single genes. This need-based preference focuses on patients with rare, life-threatening genetic diseases with limited treatment options. By modulating host immune responses or directly targeting pathogens, RNA therapy can help combat viral and bacterial infections such as COVID-19, hepatitis B, and tuberculosis. Preference exists for patients suffering from drug-resistant infections or requiring rapid response treatments during outbreaks. RNA therapy provides new treatment options for chronic kidney diseases such as polycystic kidney disease and diabetic nephropathy by targeting specific genes involved in renal function and fibrosis. RNA therapy has the potential to treat metabolic disorders, including obesity, non-alcoholic steatohepatitis (NASH), and type 2 diabetes by regulating key genes involved in glucose and lipid metabolism. In addition to cancer vaccines, RNA therapy is used to develop personalized immunotherapies for various tumor types by encoding patient-specific tumor antigens. This need-based preference targets patients with aggressive or metastatic cancers that do not respond well to standard treatments. RNA therapy helps to treat retinal diseases caused by genetic mutations, such as Leber's congenital amaurosis and age-related macular degeneration, by delivering functional copies of the affected genes directly into retinal cells.

End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.

In academic research, RNA therapy is primarily utilized for understanding gene function and regulation. Researchers employ various RNA therapeutic approaches such as small interfering RNAs (siRNAs), antisense oligonucleotides (ASOs), microRNAs (miRNAs), and messenger RNA (mRNA) therapeutics. RNA-based diagnostics focuses on detecting disease-specific biomarkers through targeted sequencing or gene expression profiling. These diagnostic methods offer increased sensitivity compared to traditional DNA-based techniques. RNA-targeted drug discovery and development involve identifying novel therapeutic targets, designing selective RNA-binding small molecules or oligonucleotides, and developing innovative delivery systems to overcome cellular barriers.

Regional Insights

The RNA therapy market in the Americas is supported by a developed healthcare sector and supportive government programs, resulting in considerable commercialization of cutting-edge RNA therapies in the United States and Canada and the evolving pharmaceutical industry in South American countries. The governments in the Americas encourage technological advancements and research activities to provide a better healthcare system to people that contribute to overall economic growth and public welfare. The governments in the Asia-Pacific region's emerging and developed economies, such as Japan, India, China, and South Korea, encourage research and development of RNA therapies. Europe has significantly adopted RNA therapies owing to the rapid commercialization and acceptability of new devices and technologies, enabling healthcare professionals to use RNA therapies. On the other hand, the surging geriatric population in Europe is expected to increase the indication of several infectious and chronic disorders. As per the Population Reference Bureau (PRB), Russia, Germany, Italy, France, the UK, Spain, Turkey, Ukraine, Poland, Nigeria, and Iran are some countries that have a significant percentage of the population aged over 65 years. The rising indication of Europe's aging population and disorders necessitates efficient RNA therapies.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the RNA Therapy Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the RNA Therapy Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the RNA Therapy Market, highlighting leading vendors and their innovative profiles. These include Alnylam Pharmaceuticals, Inc., Arbutus Biopharma Corporation, Arcturus Therapeutics Holdings Inc., Arrowhead Pharmaceuticals, Inc., AstraZeneca PLC, Benitec Biopharma Limited, Biogen Inc., BioNTech SE, Cartesian Therapeutics, Inc., Cenix BioScience GmbH, Deep Genomics, Eli Lilly and Company, F. Hoffmann-La Roche AG, GSK PLC, Ionis Pharmaceuticals, Inc., Laronde, MiNA Therapeutics Limited, Moderna, Inc., NeuBase Therapeutics, Inc., Nordic Nanovector ASA, Novartis AG, Novo Nordisk A/S, Nutcracker Therapeutics, Inc., ProQR Therapeutics N.V., Sanofi S.A., Silence Therapeutics PLC, Sirnaomics, Inc., and Triplet Therapeutics, Inc..

Market Segmentation & Coverage

This research report categorizes the RNA Therapy Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Technology
  • Enabled Technologies
    • Inhibition
    • Labeling
    • Linear amplification
    • Microarrays
    • Purification
    • qRT-PCR

• Enabling Technologies
  • RNA Antisense Technologies
    • MicroRNA
    • Small interfering RNA

• RNA Interference Technologies
• Indication
  • Cancer
  • Cardiovascular
  • Genetic Disorders
  • Infectious Diseases
  • Kidney Diseases
  • Metabolic Disorders
  • Oncology
  • Retinal Diseases

• End User
  • Academic Research
  • Diagnostics
  • Drug Discovery & Development

• Region
  • Americas
    • Argentina
    • Brazil
    • Canada
    • Mexico
    • United States
      • California
      • Florida
      • Illinois
      • New York
      • Ohio
      • Pennsylvania
      • Texas
  • Asia-Pacific
    • Australia
    • China
    • India
    • Indonesia
    • Japan
    • Malaysia
    • Philippines
    • Singapore
    • South Korea
    • Taiwan
    • Thailand
    • Vietnam

• Europe, Middle East & Africa
  • Denmark
  • Egypt
  • Finland
  • France
  • Germany
  • Israel
  • Italy
  • Netherlands
  • Nigeria
  • Norway
  • Poland
  • Qatar
  • Russia
  • Saudi Arabia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Turkey
  • United Arab Emirates
  • United Kingdom

The report offers valuable insights on the following aspects:

1. Market Penetration: It presents comprehensive information on the market provided by key players.

2. Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.

3. Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.

4. Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.

5. Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

1. What is the market size and forecast of the RNA Therapy Market?

2. Which products, segments, applications, and areas should one consider investing in over the forecast period in the RNA Therapy Market?

3. What are the technology trends and regulatory frameworks in the RNA Therapy Market?

4. What is the market share of the leading vendors in the RNA Therapy Market?

5. Which modes and strategic moves are suitable for entering the RNA Therapy Market?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Growing understanding of the role of RNA in disease pathology
    • 5.1.1.2. Heightened demand for personalized medicine
    • 5.1.1.3. Strategic alliances by pharmaceutical companies to foster novel RNA therapy development
  • 5.1.2. Restraints
    • 5.1.2.1. High costs associated with RNA therapy development processes
  • 5.1.3. Opportunities
    • 5.1.3.1. Increased investments by governments and private organizations in research and development activities
    • 5.1.3.2. Pipelined clinical trials of RNA-based therapeutics
  • 5.1.4. Challenges
    • 5.1.4.1. Issues arising from the unstable nature of RNA molecules and stringent regulatory guidelines
• 5.2. Market Segmentation Analysis
  • 5.2.1. Technology: Growing demand for enabled technologies to elevate the advancements in RNA therapies.
  • 5.2.2. Indication: Widespread applications of RNA therapy in genetic and cancer diseases.
  • 5.2.3. End User: Growing emphasis on academic research focusing on novel discoveries that propel diagnostics and drug development.
• 5.3. Market Trend Analysis
• 5.4. Cumulative Impact of High Inflation
• 5.5. Porter's Five Forces Analysis
  • 5.5.1. Threat of New Entrants
  • 5.5.2. Threat of Substitutes
  • 5.5.3. Bargaining Power of Customers
  • 5.5.4. Bargaining Power of Suppliers
  • 5.5.5. Industry Rivalry
• 5.6. Value Chain & Critical Path Analysis
• 5.7. Regulatory Framework Analysis
• 5.8. Client Customization

6. RNA Therapy Market, by Technology

• 6.1. Introduction
• 6.2. Enabled Technologies
• 6.3. Enabling Technologies

7. RNA Therapy Market, by Indication

• 7.1. Introduction
• 7.2. Cancer
• 7.3. Cardiovascular
• 7.4. Genetic Disorders
• 7.5. Infectious Diseases
• 7.6. Kidney Diseases
• 7.7. Metabolic Disorders
• 7.8. Oncology
• 7.9. Retinal Diseases

8. RNA Therapy Market, by End User

• 8.1. Introduction
• 8.2. Academic Research
• 8.3. Diagnostics
• 8.4. Drug Discovery & Development

9. Americas RNA Therapy Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific RNA Therapy Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa RNA Therapy Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. ADARx Pharmaceuticals, A Leader in Next Generation RNA Therapeutics, Announces Oversubscribed USD 200 Million Series C Financing
  • 12.3.2. ReNAgade Therapeutics enters RNA Therapy Arena with USD 300 million
  • 12.3.3. Esperovax and Ginkgo Bioworks Announce Partnership to Develop Circular RNA-based Therapeutics

13. Competitive Portfolio

• 13.1. Key Company Profiles
• 13.2. Key Product Portfolio